We are live on ! Find out more
RIGL icon

Rigel Pharmaceuticals
RIGL

163 hedge funds and large institutions have $500M invested in Rigel Pharmaceuticals in 2021 Q3 according to their latest regulatory filings, with 19 funds opening new positions, 57 increasing their positions, 43 reducing their positions, and 14 closing their positions.

New
Increased
Maintained
Reduced
Closed

36% more first-time investments, than exits

New positions opened: 19 | Existing positions closed: 14

33% more repeat investments, than reductions

Existing positions increased: 57 | Existing positions reduced: 43

15% more call options, than puts

Call options by funds: $3.32M | Put options by funds: $2.89M

3% more funds holding

Funds holding: 159 → 163 (+4)

0% more funds holding in top 10

Funds holding in top 10: 2 → 2 (0)

0.27% less ownership

Funds ownership: 8.32% → 8.05% (-0.27%)

19% less capital invested

Capital invested by funds: $614M → $500M (-$114M)

Holders
163
Holders Change
+4
Holders Change %
+2.52%
% of All Funds
2.85%
Holding in Top 10
2
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.04%
New
19
Increased
57
Reduced
43
Closed
14
Calls
$3.32M
Puts
$2.89M
Net Calls
+$430K
Net Calls Change
+$606K

Top Buyers

Rank Fund Capital Flow
1
HP
HealthInvest Partners
Sweden
+$6.95M
2
LCM
Laurion Capital Management
New York
+$4.43M
3
Dimensional Fund Advisors
Dimensional Fund Advisors
Texas
+$3.69M
4
TA
Tamarack Advisers
California
+$2.36M
5
DCM
DAFNA Capital Management
California
+$2.22M

Top Sellers

Rank Fund Capital Flow
1
Wellington Management Group
Wellington Management Group
Massachusetts
-$22.2M
2
State Street
State Street
Massachusetts
-$7.85M
3
Wells Fargo
Wells Fargo
California
-$4.4M
4
Millennium Management
Millennium Management
New York
-$2.28M
5
Citigroup
Citigroup
New York
-$1.67M
Name Holding Trade Value Shares
Change 		Change in
Stake
US Bancorp
151
US Bancorp
Minnesota
$4K – – –
Bessemer Group
152
Bessemer Group
New Jersey
$3K – – –
TWA
153
TCI Wealth Advisors
Arizona
$3K +$590 +15 +27%
CAPTRUST Financial Advisors
154
CAPTRUST Financial Advisors
North Carolina
$2K – – –
BCA
155
Berman Capital Advisors
Georgia
$1K -$236 -6 -18%
Daiwa Securities Group
156
Daiwa Securities Group
Japan
$1K – – –
GI
157
Gradient Investments
Minnesota
$1K – – –
JPLA
158
Joseph P. Lucia & Associates
New York
$1K – – –
DCM
159
Driehaus Capital Management
Illinois
– -$1.49M -34,300 Closed
GTCM
160
Gyon Technologies Capital Management
New Jersey
– -$1.15M -26,433 Closed
Tudor Investment Corp
161
Tudor Investment Corp
Connecticut
– -$625K -14,397 Closed
JIP
162
Jaffetilchin Investment Partners
Florida
– -$325K -9,293 Closed
XT
163
XTX Topco
Cayman Islands
– -$160K -3,688 Closed
DT
164
Diversified Trust
Tennessee
– -$146K -3,371 Closed
PCM
165
Pinz Capital Management
New York
– -$130K -3,000 Closed
E
166
Ergoteles
New York
– -$115K -2,640 Closed
MS
167
Maven Securities
Jersey
– -$112K -2,591 Closed
HW
168
Hancock Whitney
Mississippi
– -$89K -2,044 Closed
Lazard Asset Management
169
Lazard Asset Management
New York
– -$74K -1,709 Closed
QT
170
Quantbot Technologies
New York
– -$5K -120 Closed
ASN
171
Advisory Services Network
Georgia
– -$1K -13 Closed
APA
172
American Portfolios Advisors
New York
– -$156 -4 Closed
HCP
173
Hexagon Capital Partners
Arkansas
– +$79 +2 New
3 4 5 6
7

RIGL Hedge Fund Activity: Q3 2021 in Review

163 of the 5,712 institutional investors tracked by Wall St. Rank reported a position in Rigel Pharmaceuticals (RIGL) for Q3 2021, worth a combined $500M — down 19% from $614M a quarter earlier.

Buyers outnumbered sellers: 19 funds opened new RIGL positions and 14 closed out — a net gain of 5 holders — while 57 added to existing stakes and 43 trimmed.

The largest buyer was HealthInvest Partners, opening a new position worth an estimated $6.95M. The largest seller was Wellington Management Group, cutting an estimated $22.2M.

  • 163 institutional investors held Rigel Pharmaceuticals (RIGL) as of Q3 2021, up from 159 in Q2 2021.
  • Funds reported $500M of Rigel Pharmaceuticals stock for Q3 2021, down 19% quarter-over-quarter.
  • 19 funds opened new Rigel Pharmaceuticals positions in Q3 2021 and 14 closed out, a net change of +5 holders.
  • The largest Rigel Pharmaceuticals buyer in Q3 2021 was HealthInvest Partners, an estimated $6.95M added.
  • The largest Rigel Pharmaceuticals seller in Q3 2021 was Wellington Management Group, an estimated $22.2M sold.

Based on aggregated 13F filings for Q3 2021.